Home › Funds › BAKER BROS. ADVISORS LP › ELVN
BAKER BROS. ADVISORS LP position in ELVN
ENLIVEN THERAPEUTICS INC · Health Care
BAKER BROS. ADVISORS LP reported holding 905,191 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$41.5M, representing 0.20% of its reported portfolio and ranking #32 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed ELVN holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's ELVN position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in ELVN in Q1 2024 at 114,833 shares (US$2.0M). The position peaked in Q2 2026 at 905,191 shares, worth US$45.9M. Across 11 filings, BAKER BROS. ADVISORS LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 8 time(s). The most recent filing (Q3 2026) shows 905,191 shares valued at US$41.5M. Notable position changes include a 136% increase in Q4 2025 (shares rose 155% over the following quarter), a 234% increase in Q1 2026 (shares rose 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 114.83K | $2.02M | New |
| Q2 2024 | 114.83K | $2.68M | Hold |
| Q3 2024 | 114.83K | $2.93M | Hold |
| Q4 2024 | 114.83K | $2.58M | Hold |
| Q1 2025 | 114.83K | $2.26M | Hold |
| Q2 2025 | 114.83K | $2.30M | Hold |
| Q3 2025 | 114.83K | $2.35M | Hold |
| Q4 2025 | 271.41K | $4.18M | Add |
| Q1 2026 | 905.19K | $35.48M | Add |
| Q2 2026 | 905.19K | $45.94M | Hold |
| Q3 2026 | 905.19K | $41.49M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ELVN and 13F data
ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 56 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$310.6M), Polar Capital Holdings Plc (US$294.5M), Commodore Capital LP (US$150.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ELVN
- ORBIMED ADVISORS LLC 6.78M sh · $310.64M · Q3 2026
- Polar Capital Holdings Plc 6.43M sh · $294.53M · Q3 2026
- Commodore Capital LP 3.27M sh · $150.13M · Q3 2026
- Vestal Point Capital, LP 3.23M sh · $147.83M · Q3 2026
- Fairmount Funds Management LLC 1.86M sh · $85.06M · Q3 2026
- Siren, L.L.C. 1.48M sh · $67.62M · Q3 2026
- Bellevue Group AG 1.47M sh · $67.34M · Q3 2026
- Logos Global Management LP 1.08M sh · $49.51M · Q3 2026
- First Light Asset Management, LLC 1.02M sh · $46.68M · Q3 2026
- Novo Holdings A/S 1.00M sh · $45.84M · Q3 2026
- First Turn Management, LLC 958.70K sh · $43.95M · Q3 2026
- SAMLYN CAPITAL, LLC 936.17K sh · $42.91M · Q3 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held ELVN?
BAKER BROS. ADVISORS LP has disclosed ELVN holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is BAKER BROS. ADVISORS LP's current position in ELVN?
As of Q3 2026, BAKER BROS. ADVISORS LP holds 905.19K shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $41.49M, representing 0.20% of its reported portfolio and ranking #32.
Has BAKER BROS. ADVISORS LP been buying or selling ELVN?
In the latest 13F filing (Q3 2026), BAKER BROS. ADVISORS LP held unchanged its position in ELVN. The position peaked in Q2 2026 at 905.19K shares.
Which other funds hold ELVN?
Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Commodore Capital LP, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.